ZLSCF (ZYUS Life Sciences) Short-Term Debt: $10.71 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLSCF ZYUS Life Sciences Corp ZLSCF
21 GF Score
Price $0.60
GF Value $0.55
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is ZYUS Life Sciences Short-Term Debt?

ZYUS Life Sciences ZLSCF -6.89% 21 Short-Term Debt is $10.71 Mil as of Jun. 2026. GuruFocus rates ZLSCF with a GF Score™ of 21/100 and a GF Value™ of $0.55 (Fairly Valued). The stock has 6 warning signs investors should review.

ZYUS Life Sciences's Short-Term Debt for the quarter that ended in Jun. 2026 was $10.71 Mil.

ZYUS Life Sciences's quarterly Short-Term Debt increased from Dec. 2025 ($0.89 Mil) to Mar. 2026 ($6.97 Mil) and increased from Mar. 2026 ($6.97 Mil) to Jun. 2026 ($10.71 Mil).

ZYUS Life Sciences's annual Short-Term Debt increased from Dec. 2023 ($4.97 Mil) to Dec. 2024 ($6.62 Mil) but then declined from Dec. 2024 ($6.62 Mil) to Dec. 2025 ($0.89 Mil).

ZYUS Life Sciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

ZYUS Life Sciences Short-Term Debt Related Terms

ZYUS Life Sciences Short-Term Debt Historical Data

* Premium members only.

The historical data trend for ZYUS Life Sciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences Short-Term Debt Chart

ZYUS Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.76 4.97 6.62 0.89

ZYUS Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.75 5.05 0.89 6.97 10.71
ZLSCF
21GF Score
ZYUS Life Sciences Corp ZLSCF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $10.71 Mil mean?
ZYUS Life Sciences (ZLSCF) has a Short-Term Debt of $10.71 Mil as of Jun. 2026.
Is ZYUS Life Sciences' Short-Term Debt too high?
ZYUS Life Sciences' current Short-Term Debt is $10.71 Mil. Overall, ZYUS Life Sciences has a GF Score™ of 21/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' Short-Term Debt compare to SKYI and CBDY?
ZYUS Life Sciences' Short-Term Debt of $10.71 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. ZYUS Life Sciences's current Short-Term Debt is $10.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Fairly Valued. The stock's GF Value™ is $0.55, compared to a current price of $0.60 — trading 9.1% above its estimated fair value. The current Short-Term Debt is $10.71 Mil. ZYUS Life Sciences' overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current Short-Term Debt is $10.71 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ZYUS Life Sciences (ZLSCF) Overvalued in 2026?

Based on GuruFocus' analysis, ZYUS Life Sciences stock appears to be overvalued. The current stock price of $0.60 is trading 9.1% above its estimated GF Value™ of $0.55. GuruFocus considers ZYUS Life Sciences to be Fairly Valued.

Key valuation signals for ZLSCF:

  • Short-Term Debt: $10.71 Mil
  • GF Value™: $0.55 vs. price of $0.60 (9.1% above fair value)
  • GF Score™: 21/100 with 6 warning signs

No single metric tells the full story. See the ZLSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ZYUS Life Sciences Business Description

Other Exchanges ZYUS:Canada
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
21GF Score

Get the complete analysis for ZLSCF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price
$0.55
GF Value